Journal Report

EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH

Download PDF
Journal Information
Journal Title
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH
Publisher
TAYLOR & FRANCIS LTD
ISSN
1473-7167
E-ISSN
1744-8379
Database
Clarivate
Domain
Health Sciences, Life Sciences, Physical Sciences, Social Sciences
Classification History
Year A+ A B C
2026 ✓ ✓
2025 ✓ ✓
2024 ✓ ✓
2023 ✓ ✓
2021/2022 ✓ ✓
2020 ✓ ✓
2019 ✓ ✓
2018 ✓
A journal may have more than one classification in the same year. All recorded classifications are displayed.
Recent Articles
Cost-effectiveness analysis of sintilimab versus docetaxel as second-line therapy for squamous non-small cell lung cancer in China
Yanhui Li, Yafei Shi
2026-11-11 Pages 1-10
DOI: 10.1080/14737167.2026.2757896
Current and emerging measures and methods for evaluating medication adherence behaviors
Fernando Fernandez-Llimos, M. Margarida Castel-Branco, Isabel V. Figueiredo et al.
2026-11-9 Pages 1-16
DOI: 10.1080/14737167.2026.2760608
Drug acquisition accounts for a minor share of the costs associated with dobutamine–milrinone escalation in cardiogenic shock: a propensity-weighted cost analysis from Indonesia
Ryeska Fajar Respaty, Santi Purna Sari, Bambang Widyantoro
2026-11-5 Pages 1-10
DOI: 10.1080/14737167.2026.2760016
Cost-effectiveness analysis of finotonlimab in combination with bevacizumab biosimilar SCT510 as first-line therapy for advanced hepatocellular carcinoma
Ying He, Maojin You
2026-11-5 Pages 1-12
DOI: 10.1080/14737167.2026.2760014
Cost-effectiveness analysis of dostarlimab plus chemotherapy versus chemotherapy as first-line treatment of metastatic non-squamous non-small cell lung cancer
Chang Cheng, Tong Liu
2026-11-4 Pages 1-11
DOI: 10.1080/14737167.2026.2760022
An expert-AI co-creation framework for robust health economic simulations
Anna Machens, Hendrik Koffijberg, Shiva Faeghi
2026-11-4 Pages 1-13
DOI: 10.1080/14737167.2026.2755647
Affordability and relative economic burden of multiple sclerosis biologics in South America: a cross-country analysis of prices, purchasing power and regulatory access
Priscila Madeira da Silva Oliveira, Cid Manso de Mello Vianna, Alfonso Jesus Gil Lopez et al.
2026-11-2 Pages 1-15
DOI: 10.1080/14737167.2026.2757886
Potential savings in Medicaid antiseizure medication reimbursement, 2008–2025: persistent brand-name reimbursement despite generic availability
Tengizi Mtchedlidze, Jeetendra Sah, Giorgi Modebadze et al.
2026-11-2 Pages 1-10
DOI: 10.1080/14737167.2026.2757890
Cost-effectiveness of neoadjuvant/adjuvant pembrolizumab versus standard of care for locally advanced head and neck squamous cell carcinoma in China and the United States
Ruixuan Liu, Zhen Wang, Xueli Yang et al.
2026-11-2 Pages 1-11
DOI: 10.1080/14737167.2026.2757910
National long-term trends in benzodiazepine outpatients prescription claims, Medicaid reimbursement, and average reimbursement per prescription in the United States, 2010–2024
Yara A Alharbi, Yusra I Alghamdi, Jana H Alshaikh et al.
2026-11-2
DOI: 10.1080/14737167.2026.2757900
Articles retrieved from Crossref.
Green Journals | https://www.green-journals.com | info@green-journals.com
Printed: November 13, 2026 08:57